Is CRSP a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on First-Mover Advantage in Commercial Gene Editing, with revenue (full year 2025, product only) at ~$3.5 million. The bear case rests on the commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments. Analysts covering it are spread from $44.00 to $291.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $44.00, -6.9% from the $47.27 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

First-Mover Advantage in Commercial Gene Editing. Casgevy is the world's first approved CRISPR-based medicine, giving CRISPR Therapeutics a durable head start in manufacturing know-how, regulatory relationships, and patient community trust. The most optimistic analyst target on CRSP is $291.00, +515.6% from the $47.27 price. That figure is only reachable if this thesis works close to its best case.

The commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments. The expiration of CRISPR's cost-deferral agreement with Vertex drove collaboration expenses up roughly 77 percent year over year in 2025, contributing to a full-year operating loss of approximately $665 million, and the company must repay around $222 million in previously deferred costs before net cash flows from Casgevy accrue to CRSP shareholders. Competing gene-editing and cell-therapy platforms from Intellia Therapeutics, Beam Therapeutics, and large pharmaceutical companies pursuing in vivo approaches could erode CRSP's differentiation over time. The stock also carries high short interest, above 22 percent of shares outstanding as of recent data, reflecting meaningful institutional skepticism about the pace of the commercial ramp. The most pessimistic published target is $44.00, -6.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (First-Mover Advantage in Commercial Gene Editing) stalling in the reported numbers rather than in the narrative, the risk above (the commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

CRISPR Therapeutics uses its CRISPR/Cas9 gene editing platform to develop medicines for serious diseases. Its only approved product is Casgevy, co-developed with Vertex Pharmaceuticals, which is the world's first CRISPR-based therapy and targets sickle cell disease and transfusion-dependent beta-thalassemia. Its pipeline spans CAR-T cancer therapies, cardiovascular gene editing, and an acquired siRNA program.

That depends entirely on an investor's risk tolerance and time horizon. CRSP offers exposure to a genuinely first-of-its-kind commercial gene-editing asset and a broad pipeline, but the company is deeply unprofitable, burning several hundred million dollars per year, with Casgevy's commercial ramp proving very slow. Analysts hold widely divergent views, with price targets ranging from around $33 to over $80.

No. CRISPR Therapeutics does not pay a dividend. The company is pre-profitability with significant annual operating losses, and its capital is directed entirely toward clinical development and the commercial rollout of Casgevy. Investors seeking income from dividends would need to look elsewhere in the biotech or broader healthcare sector.